Biosimilar sponsors like the new user fee agreement because of its potential to reduce the number of necessary formal meeting requests and by extension speed development.
BsUFA III will create a new meeting type allowing sponsors to schedule a discussion with the US Food and Drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?